Aptorum Group Ltd (APM)

$3.84

-0.47

(-10.9%)

Market is closed - opens 7 PM, 18 Jul 2024

Performance

  • $3.55
    $4.16
    $3.84
    downward going graph

    7.55%

    Downside

    Day's Volatility :14.66%

    Upside

    7.69%

    downward going graph
  • $1.35
    $17.49
    $3.84
    downward going graph

    64.84%

    Downside

    52 Weeks Volatility :92.28%

    Upside

    78.04%

    downward going graph

Returns

PeriodAptorum Group LtdIndex (Russel 2000)
3 Months
-28.49%
0.0%
6 Months
115.73%
0.0%
1 Year
71.43%
0.0%
3 Years
-86.04%
-18.2%

Highlights

Market Capitalization
23.6M
Book Value
$4.8
Earnings Per Share (EPS)
-0.62
Wall Street Target Price
80.0
Profit Margin
0.0%
Operating Margin TTM
-2486.04%
Return On Assets TTM
-32.3%
Return On Equity TTM
-37.4%
Revenue TTM
431.4K
Revenue Per Share TTM
0.1
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
81.9K
EBITDA
-9.6M
Diluted Eps TTM
-0.62
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.64
EPS Estimate Next Year
-0.84
EPS Estimate Current Quarter
-0.27
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 6 Wall street analysts offering stock ratings for Aptorum Group Ltd(by analysts ranked 0 to 5 stars)
Based on 6 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
5
5
5
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1983.33%

Current $3.84
Target $80.00

Company Financials

FY18Y/Y Change
Revenue
383.5K
-
Net Income
-14.8M
↑ 482.22%
Net Profit Margin
-3.9K%
-
FY19Y/Y Change
Revenue
535.2K
↑ 39.57%
Net Income
-20.9M
↑ 40.61%
Net Profit Margin
-3.9K%
↓ 28.87%
FY20Y/Y Change
Revenue
911.5K
↑ 70.32%
Net Income
7.1M
↓ 133.89%
Net Profit Margin
775.29%
↑ 4672.13%
FY21Y/Y Change
Revenue
1.5M
↑ 69.15%
Net Income
-25.3M
↓ 457.84%
Net Profit Margin
-1.6K%
↓ 2415.5%
FY22Y/Y Change
Revenue
1.3M
↓ 15.95%
Net Income
-5.3M
↓ 78.98%
Net Profit Margin
-410.1%
↑ 1230.11%
FY23Y/Y Change
Revenue
431.4K
↓ 66.71%
Net Income
-2.8M
↓ 46.85%
Net Profit Margin
-654.8%
↓ 244.7%
Q1 FY22Q/Q Change
Revenue
-1.3M
-
Net Income
-2.2M
-
Net Profit Margin
177.14%
-
Q2 FY22Q/Q Change
Revenue
527.5K
↓ 142.03%
Net Income
-1.9M
↓ 15.19%
Net Profit Margin
-357.42%
↓ 534.56%
Q1 FY23Q/Q Change
Revenue
768.4K
↑ 45.68%
Net Income
-7.9M
↑ 319.8%
Net Profit Margin
-1.0K%
↓ 672.52%
Q3 FY23Q/Q Change
Revenue
431.4K
↓ 43.86%
Net Income
-5.5M
↓ 30.67%
Net Profit Margin
-1.3K%
↓ 242.05%
FY18Y/Y Change
Total Assets
45.1M
↑ 42.82%
Total Liabilities
12.3M
↑ 826.46%
FY19Y/Y Change
Total Assets
24.0M
↓ 46.86%
Total Liabilities
9.1M
↓ 26.17%
FY20Y/Y Change
Total Assets
44.2M
↑ 84.65%
Total Liabilities
6.1M
↓ 33.22%
FY21Y/Y Change
Total Assets
21.9M
↓ 50.47%
Total Liabilities
4.4M
↓ 27.6%
FY22Y/Y Change
Total Assets
20.9M
↓ 4.75%
Total Liabilities
13.0M
↑ 196.15%
FY23Y/Y Change
Total Assets
20.6M
↓ 1.09%
Total Liabilities
5.3M
↓ 59.67%
Q4 FY22Q/Q Change
Total Assets
20.9M
↓ 13.12%
Total Liabilities
13.0M
↑ 55.73%
Q1 FY23Q/Q Change
Total Assets
20.9M
↑ 0.0%
Total Liabilities
13.0M
↑ 0.0%
Q2 FY23Q/Q Change
Total Assets
14.4M
↓ 30.94%
Total Liabilities
1.6M
↓ 87.47%
Q3 FY23Q/Q Change
Total Assets
14.4M
↑ 0.0%
Total Liabilities
1.6M
↑ 0.0%
Q4 FY23Q/Q Change
Total Assets
20.6M
↑ 43.21%
Total Liabilities
5.3M
↑ 221.99%
Q1 FY24Q/Q Change
Total Assets
20.6M
↑ 0.0%
Total Liabilities
5.3M
↑ 0.0%
FY18Y/Y Change
Operating Cash Flow
-10.0M
↑ 73.54%
Investing Cash Flow
-6.1M
↓ 147.35%
Financing Cash Flow
25.5M
↑ 180.54%
FY19Y/Y Change
Operating Cash Flow
-13.4M
↑ 33.35%
Investing Cash Flow
-108.1K
↓ 98.22%
Financing Cash Flow
-7.3M
↓ 128.74%
FY20Y/Y Change
Operating Cash Flow
-15.9M
↑ 19.05%
Investing Cash Flow
1.8M
↓ 1804.74%
Financing Cash Flow
12.4M
↓ 269.62%
FY21Y/Y Change
Operating Cash Flow
-14.7M
↓ 8.04%
Investing Cash Flow
16.5M
↑ 796.07%
Financing Cash Flow
2.8M
↓ 77.61%
Q1 FY22Q/Q Change
Operating Cash Flow
3.3B
↑ 0.0%
Investing Cash Flow
1.4M
↑ 0.0%
Financing Cash Flow
32.8B
↑ 0.0%
Q2 FY22Q/Q Change
Operating Cash Flow
-6.8M
↓ 100.2%
Investing Cash Flow
1.4M
↑ 0.0%
Financing Cash Flow
3.0M
↓ 99.99%

Technicals Summary

Sell

Neutral

Buy

Aptorum Group Ltd is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Aptorum Group Ltd
Aptorum Group Ltd
-14.67%
115.73%
71.43%
-86.04%
-98.29%
Moderna, Inc.
Moderna, Inc.
-6.91%
25.22%
1.18%
-60.44%
769.95%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
4.48%
16.73%
49.42%
85.5%
258.18%
Novo Nordisk A/s
Novo Nordisk A/s
-3.82%
25.91%
69.01%
206.62%
460.98%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.51%
12.79%
36.04%
145.12%
174.23%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Aptorum Group Ltd
Aptorum Group Ltd
NA
NA
NA
-0.64
-0.37
-0.32
NA
4.8
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
32.36
32.36
1.46
44.28
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
48.58
48.58
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.75
31.75
0.53
17.06
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Aptorum Group Ltd
Aptorum Group Ltd
Buy
$23.6M
-98.29%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$48.0B
769.95%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$120.7B
258.18%
32.36
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$631.0B
460.98%
48.58
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.2B
174.23%
31.75
39.46%

Insights on Aptorum Group Ltd

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 205.5% return, outperforming this stock by 291.9%

Institutional Holdings

  • Geode Capital Management, LLC

    0.72%
  • Murchinson Ltd.

    0.26%
  • Morgan Stanley - Brokerage Accounts

    0.06%
  • Tower Research Capital LLC

    0.03%

Company Information

aptorum group limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers. its pipeline through the establishment of drug discovery platforms enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. the company is also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. it also has projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms. aptorum group limited was incorporated in 2010 and is headquartered in london, the united kingdom.

Organization
Aptorum Group Ltd
Employees
3
CEO
Mr. Chung Yuen Huen
Industry
Health Technology

FAQs